{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Determination of antibodies against BL22 is determined by the Clinical Laboratory Improvement Amendments (CLIA) certified blood tests in our contract lab. NCI-Frederick in the laboratory of Dr. David Waters (Science Applications International Corporation (SAIC). He is CLIA certified.","groups":[{"description":"30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.","id":"OG000","title":"BL22 Immunotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Percentage of Patients Who Make Antibodies","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}